The incremental cost of disease progression among patients with metastatic stage IIIB or IV non-small cell lung cancer versus those without progression was $12,327 for 3 postprogression months.
Kathleen M. Fox, MHS, PhD
Advertisement
Articles by Kathleen M. Fox, MHS, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
2
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
3
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
4
Pulmonary Embolism Can Affect Elite Athletes, Too: Samantha Pettigrew, MD
5